Javascript must be enabled to continue!
Abstract 1760: Mutational landscape of the canine acute myeloid leukemia exome
View through CrossRef
Abstract
Over 21,000 newly diagnosed cases of human acute myeloid leukemia (hAML) and 10,000 hAML-related deaths are reported in the United States every year. hAML is considered a highly diverse aggressive hematopoietic malignancy, with over 16 recurrent gene rearrangements, 60 recurrent point mutations, and hundreds of rarely mutated genes. There are large ongoing multi-institutional studies devoted to advancing medical management for hAML by providing targeted therapeutics to patients based on their molecular characteristics. A preclinical spontaneous large animal model for testing novel therapies could accelerate the development of better treatments in people. Dogs spontaneously develop AML with similar clinical features and outcomes. As such, the dog may be a useful pre-clinical model, but little is known about the molecular landscape and/or drivers of canine AML (cAML). The goal of this work was to identify somatic mutation candidates in cAML and determine the overlapping features with hAML. We utilized whole exome sequencing at 300x coverage to identify candidate mutations in 51 cAML samples. Somatic variant calling was performed per the GATK best practice recommendations using Mutect2 and a reference panel of normals (n=77) and a variant call file of canine germline variants. We focused our analysis on novel variants predicted to have a moderate to high impact and that occurred in genes implicated in cancer. At least one variant was identified in genes involved in the RTK/RAS pathway (e.g. NRAS, KRAS, PTPN11, FLT3, KIT) in over 75% of cAML samples, a trend that is also found in people. Additionally, recurrent point mutations were predicted in NRAS and KRAS, and some of which, such as the codon changes G13R and Q61R/H in NRAS, were noted to be shared between hAML and cAML. Mutations in DNMT3A were uncommon (n=3/44) and NPM1 mutations were not identified in our cohort, both of which are common hAML-associated genes. However, mutations in other epigenetic modifiers, such as KDM5C and KDM6A, occurred at a high frequency. This data provides insight into the candidate mutations potentially driving cAML pathogenesis and highlights the overlapping molecular features with hAML.
Citation Format: Robert Harris, Evan Conaway, Anne Avery. Mutational landscape of the canine acute myeloid leukemia exome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1760.
American Association for Cancer Research (AACR)
Title: Abstract 1760: Mutational landscape of the canine acute myeloid leukemia exome
Description:
Abstract
Over 21,000 newly diagnosed cases of human acute myeloid leukemia (hAML) and 10,000 hAML-related deaths are reported in the United States every year.
hAML is considered a highly diverse aggressive hematopoietic malignancy, with over 16 recurrent gene rearrangements, 60 recurrent point mutations, and hundreds of rarely mutated genes.
There are large ongoing multi-institutional studies devoted to advancing medical management for hAML by providing targeted therapeutics to patients based on their molecular characteristics.
A preclinical spontaneous large animal model for testing novel therapies could accelerate the development of better treatments in people.
Dogs spontaneously develop AML with similar clinical features and outcomes.
As such, the dog may be a useful pre-clinical model, but little is known about the molecular landscape and/or drivers of canine AML (cAML).
The goal of this work was to identify somatic mutation candidates in cAML and determine the overlapping features with hAML.
We utilized whole exome sequencing at 300x coverage to identify candidate mutations in 51 cAML samples.
Somatic variant calling was performed per the GATK best practice recommendations using Mutect2 and a reference panel of normals (n=77) and a variant call file of canine germline variants.
We focused our analysis on novel variants predicted to have a moderate to high impact and that occurred in genes implicated in cancer.
At least one variant was identified in genes involved in the RTK/RAS pathway (e.
g.
NRAS, KRAS, PTPN11, FLT3, KIT) in over 75% of cAML samples, a trend that is also found in people.
Additionally, recurrent point mutations were predicted in NRAS and KRAS, and some of which, such as the codon changes G13R and Q61R/H in NRAS, were noted to be shared between hAML and cAML.
Mutations in DNMT3A were uncommon (n=3/44) and NPM1 mutations were not identified in our cohort, both of which are common hAML-associated genes.
However, mutations in other epigenetic modifiers, such as KDM5C and KDM6A, occurred at a high frequency.
This data provides insight into the candidate mutations potentially driving cAML pathogenesis and highlights the overlapping molecular features with hAML.
Citation Format: Robert Harris, Evan Conaway, Anne Avery.
Mutational landscape of the canine acute myeloid leukemia exome [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1760.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract
Abstract 1606
Introduction:
Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
Abstract 1772: A naturally occurring canine model of peripheral T-cell lymphoma, not otherwise specified
Abstract 1772: A naturally occurring canine model of peripheral T-cell lymphoma, not otherwise specified
Abstract
Despite being the most common subtype of human peripheral T-cell lymphoma (PTCL), PTCL-not otherwise specified (PTCL-NOS) remains a poorly understood diagno...
Abstract 132: African polyherbal formulation alleviates benzene-induced leukemia in Wistar rats
Abstract 132: African polyherbal formulation alleviates benzene-induced leukemia in Wistar rats
Abstract
Background: Chemotherapy and radiotherapy are effective cancer treatment options but they are accompanied by serious side effects. Therefore, more effective...
A Systematic Literature Review on Leukemia Prediction Using Machine Learning
A Systematic Literature Review on Leukemia Prediction Using Machine Learning
Blood cancer is one of the most dangerous diseases in kids because it spreads throughout the body, damages healthy cells, and causes uncontrolled white blood cell growth. If it is ...
EphB4 Expression and Biological Significance in Drug Resistance of Myeloid Leukemia
EphB4 Expression and Biological Significance in Drug Resistance of Myeloid Leukemia
Abstract
Abstract 4725
Chemotherapy is widely used in treatment of myeloid leukemia, the efficancy of which, however, is often hampered by the develop...

